Friday 7 August 2020
Home      All news      Contact us      India
business-standard - 1 month ago

Cipla, Boehringer Ingelheim to co-sell 3 oral anti-diabetic drugs in India

Pharma major Cipla and drug firm Boehringer Ingelheim India on Monday announced partnership to co-market three new oral anti-diabetic drugs in the country. The companies have entered into a partnership for co-marketing three new oral anti-diabetics drugs --- Oboravo (Empagliflozin),Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India, Cipla and Boehringer Ingelheim India Pvt Ltd said in a statement. As per the International Diabetes Federation, India is home to 7.7 crore diabetic adults aged between 20-79 years, ranking second behind China, and is poised to reach 13.42 crore patients by 2045, it added. Diabetes continues to be a focus area for Cipla and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access and reach capabilities, we will be at the forefront of providing holistic diabetes care, Cipla India Business Executive VP CEO Nikhil Chopra said. In a similar vein, Boehringer ...


Latest News
Hashtags:   

Cipla

 | 

Boehringer

 | 

Ingelheim

 | 

diabetic

 | 

drugs

 | 

India

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Sources